Palpable vs non-palpable breast cancers in screened populations: Clinicopathological features and prognostic implications

Table 1 The clinicopathologic characteristics of the two subgroups, median (SD)

Variable		Entire cohort		Palpability				P value
				No		Yes
		n	%	n	%	n	%
Patients		2110	100	876	41.5	1234	58.5	NS
Age	≤ 50	604	28.6	249	28.4	355	28.8	NS
	> 50	1506	71.4	627	71.6	879	71.2
Tumor size (mm)		14.8 (8.5)		11 (6.7)		17.5 (8.6)		< 0.001
Surgical technique	Oncoplasty	1314	62.3	646	73.7	668	54.1	< 0.001
	Traditional	796	37.7	230	26.3	566	45.9
Histotype	Infiltrating ductal carcinoma	1785	84.6	758	86.5	1027	83.3	NS
	Infiltrating lobular carcinoma	236	11.2	85	9.7	151	12.2
	Other	89	4.2	33	3.8	56	4.5
Grading	1	637	30.2	338	38.6	299	24.2	< 0.001
	2	915	43.3	388	44.3	525	42.5
	3	550	26.1	143	16.3	407	33
	Not assessable	9	0.4	6	0.7	3	0.2
Multifocality	No	1841	87.3	744	84.9	1097	88.9	0.007
	Yes	269	12.7	132	15.1	137	11.1
Limphovascular invasion	No	1722	81.6	725	82.8	997	80.8	NS
	Yes	388	18.4	151	17.2	237	19.2
N	N+	486	23	146	16.7	340	27.6	< 0.001
	N0	1621	76.9	729	83.2	892	72.3
	Nx	3	0.1	1	0.1	2	0.2
Subtype1	HER2+	61	2.9	24	2.7	37	3	< 0.001
	HER2 HRP+	134	6.4	56	6.4	78	6.3
	Luminal A	1269	60.1	611	69.7	658	53.3
	Luminal B	492	23.3	128	15.8	354	28.7
	Triple negative	146	6.9	42	4.8	104	8.4
Ki67		19.8 (15.6)		15.9 (13.8)		22.5 (16.2)		< 0.001
R1 rate		194	9.2	96	11	98	7.9	< 0.005

¹Missing data, n = 8.

HER2: Human epidermal receptor 2; NS: Not significant.